medigraphic.com
ISSN 1405-8871 (Print)

2021, Number 1

<< Back Next >>

Aten Fam 2021; 28 (1)

Diagnostic Approach and Management of Psoriasis in Primary Care

Luna CE, Flores CAA, Bonilla HR, Vichi LLJ, Gómez GAK

Language: Spanish
References: 37
Page: 54-61
PDF size: 401.43 Kb.


ABSTRACT

Psoriasis is a chronic, multifactorial and inflammatory disease which primarily affects skin and joints, and has a prevalence of 2% of the world population. In the skin, the most frequently affected organ, is characterized by the production of erythematous plaques covered by scales. Psoriasis has an important genetic component, related to alterations in the major complex of histocompatibility. This entity is characterized by abnormalities in the control of innate and adaptive immunity, facilitating a chronic state of inflammation. Psoriasis manifests itself in different phenotypes including psoriasis vulgaris or plaques, guttate psoriasis, inverse psoriasis, pustular psoriasis and erythrodermic psoriasis. Most of these phenotypes have a cyclical evolution with outbreaks and relapses. Psoriasis has been associated with multiple rheumatological, cardiovascular and metabolic comorbidities that significantly impact the patient’s life. The initial approach and management of this disorder are fundamental in the practice of the family physician, the objective of generating an early reference and avoiding serious complications. This article recapitulates the most relevant aspects in the diagnosis, early recognition of comorbidities, and management of psoriasis at the Primary care level.


REFERENCES

  1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.

  2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-12.

  3. Chanussot C, & Arenas, R. Psoriasis. Estudio descriptivo y comorbilidades en 114 pacientes. Dermatología, cosmética y quirúrgica. 2015;1(13):19-24.

  4. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450-6.

  5. Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6(5):813-20.

  6. Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8:15382.

  7. Gudjonsson JE, Elder JT. Psoriasis. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. Fitzpatrick’s Dermatology, 9e. New York, NY: McGraw-Hill Education; 2019.

  8. Buchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol. 2007;25(6):616-24.

  9. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564-9.

  10. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest. 1994;94(1):202-9.

  11. Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5(1):9-19.

  12. Hao JQ. Targeting interleukin-22 in psoriasis. Inflammation. 2014;37(1):94-9.

  13. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008;28(1):29-39.

  14. Hurt MA, Weedon D. Weedon D. Weedon’s Skin Pathology. 3rd ed. London: Churchill Livingstone Elsevier, 2010. Dermatology Practical & Conceptual. 2012;2(1):79-82.

  15. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii30-6.

  16. Thappa DM. The isomorphic phenomenon of Koebner. Indian journal of dermatology, venereology and leprology. 2004;70:187-9.

  17. Prignano F, Ricceri F, Pescitelli L, Lotti T. Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clinical, cosmetic and investigational dermatology. 2009;2:9-13.

  18. Fernández-Guarino M, Harto A, Jaén P. Psoriasis ungueal. Piel. 2007;22(7):346-51.

  19. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4-5):490-5.

  20. Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016;3(1):79-82.

  21. Adler DJ, Rower JM, Hashimoto K. Annular pustular psoriasis. Arch Dermatol. 1981;117(5):313-4.

  22. Young M, Aldredge L, Parker P. Psoriasis for the primary care practitioner. J Am Assoc Nurse Pract. 2017;29(3):157-78.

  23. Micali G, Verzì AE, Giuffrida G, Panebianco E, Musumeci ML, Lacarrubba F. Inverse Psoriasis: From Diagnosis to Current Treatment Options. Clinical, cosmetic and investigational dermatology. 2019;12:953-9.

  24. Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21(5 Pt 1):985-91.

  25. Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983-94.

  26. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957-70.

  27. Krakowski P, Gerkowicz A, Pietrzak A, Krasowska D, Jurkiewicz A, Gorzelak M, et al. Psoriatic arthritis - new perspectives. Arch Med Sci. 2019;15(3):580-9.

  28. Trafford AM, Parisi R, Kontopantelis E, Griffiths CEM, Ashcroft DM. Association of Psoriasis With the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis. JAMA Dermatology. 2019;155(12):1390-403.

  29. Fu Y, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(12):1417-23.

  30. Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A metaanalysis of observational studies. PLoS One. 2017;12(7):e0181039.

  31. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215-25.

  32. Matza LS, Brazier JE, Stewart KD, Pinto L, Bender RH, Kircik L, et al. Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). J Med Econ. 2019;22(9):936-44.

  33. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-85.

  34. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50.

  35. Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013(3):Cd005028.

  36. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48(5):760-7.

  37. Del Rosso JQ, Kircik L, Lin T, Pillai R. Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential. The Journal of clinical and aesthetic dermatology. 2019;12(1):11-5.




2020     |     www.medigraphic.com